**ETCTN Trials by Disease/Treatment Area: Gastrointestinal Cancer**

- **10058**: A Phase I Study of Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) with Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum

- **10181**: A Phase II Study of Savolitinib in Subjects with MET Amplified Metastatic Colorectal Cancer

- **10066**: A Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)

- **10211**: A Phase 2 Single-Arm Study of M6620 in Combination with Irinotecan in Patients with Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer

- **10222**: Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH) - Mutant Solid Tumors (2 cohorts: cholangiocarcinoma and other solid tumors)

- **10129**: A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors (3 cohorts: glioma, cholangiocarcinoma, and other solid tumors)

- **9881**: A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors (4 cohorts: NSCLC, TNBC, PDAC, and SCLC)

- **9676**: A Phase I Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors (Expansion phase, pt. 1 includes melanoma, renal cell, ovarian, and colorectal cancer)

- **10366**: A Phase 1/2 Study of M3814 in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma